We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2019 to Jul 2024
Drug maker GW Pharmaceuticals PLC (GWP.LN) Tuesday said it has entered a strategic alliance with a U.K. university to further its research into the use of cannabis to treat diabetes and other metabolic diseases.
GW, which has filed its cannabis-derived drug Sativex for regulatory approval following a successful phase three trial in March, said it entered an alliance with Professor Mike Cawthorne and the Clore Laboratory at the University of Buckingham, England.
The alliance will research cannabis-derived compounds, or cannabinoids, in the field of diabetes and metabolic disease. Prof. Cawthorne is a former director of diabetes research at Smithkline Beecham, a forerunner of GlaxoSmithKline PLC (GSK.LN), where he and his team discovered the best-selling diabetes drug Avandia.
The alliance will provide GW with dedicated facilities to undertake preclinical work on cannabinoids and exclusive access to therapies under evaluation at the Clore lab, the company said.
Company Web site: www.gwpharm.com
-By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
